|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 38/13 | (2006.01) |
| A61P 31/14 | (2006.01) |
| (11) | Number of the document | 1663287 |
| (13) | Kind of document | T |
| (96) | European patent application number | 04764762.3 |
| Date of filing the European patent application | 2004-09-02 | |
| (97) | Date of publication of the European application | 2006-06-07 |
| (45) | Date of publication and mention of the grant of the patent | 2009-07-15 |
| (46) | Date of publication of the claims translation | 2009-11-25 |
| (86) | Number | PCT/EP2004/009804 |
| Date | 2004-09-02 |
| (87) | Number | WO 2005/021028 |
| Date | 2005-03-10 |
| (30) | Number | Date | Country code |
| 0320638 | 2003-09-03 | GB |
| (72) |
HIJIKATA, Makoto, JP
SHIMOTOHNO, Kunitada, JP
WATASHI, Koichi, JP
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
Novartis Pharma GmbH, Brunner Strasse 59, 1230 Wien, AT |
| (74) |
Marius JAKULIS - JASON,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Modifikuotų ciklosporinų panaudojimas HCV sutrikimų gydymui |
| USE OF MODIFIED CYCLOSPORINS FOR THE TREATMENT OF HCV DISORDERS |
| Payment date | Validity (years) | Amount | |
| 2019-08-30 | 16 | 347.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2020-09-02 |